Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
about
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapyPleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future PerspectivesModulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsSomething old, something new and something very old: drugs for treating type 2 diabetesPeroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a reviewResidual macrovascular risk in 2013: what have we learned?Role of lipotoxicity in endothelial dysfunctionPPARgamma-Dependent Control of Renin Expression: Molecular Mechanisms and Pathophysiological RelevanceFibrates, glitazones, and peroxisome proliferator-activated receptorsComparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytesPPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.Minireview: Challenges and opportunities in development of PPAR agonistsOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.New frontiers in the treatment of diabetic dyslipidemiaMolecular determinants of the cardiometabolic phenotype.Brown fat as a therapy for obesity and diabetes.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.Pharmacological and non-pharmacological interventions to influence adipose tissue function.Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.Emerging drugs for hyperlipidemia.Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.Discontinued in 2013: diabetic drugs.Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancerImpaired lipid metabolism in idiopathic pulmonary alveolar proteinosis.Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).Diabetes mellitus: new challenges and innovative therapies.Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseasesPeroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular systemCardiometabolic interventions - focus on transcriptional regulators.Established and emerging approaches for the management of dyslipidaemia.Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
P2860
Q24616813-B801441B-13B8-40DF-BF52-46C6B6CB6DDFQ26747009-B69BDF76-DC57-4925-925E-FA1C87BE27F4Q26829098-F8AA249B-E6C1-4650-9B6A-256689482247Q26865663-E8D7F255-1CD8-4A7A-968E-C7CAE131F6DCQ26866784-94B90856-D6E2-4AA6-9982-107D3D8712F2Q26996039-086B6965-65B7-4E4E-9FDC-31F920D51320Q27000731-E786405D-0B57-4F70-B212-0FF85FC5703CQ27009036-A1256FB5-1F4E-4632-8D89-3808BB86A66CQ28279732-EBC17E08-90F9-4CE0-AE0F-74BA4A1BD0CFQ28730590-BF9185F6-02F9-4E10-9B63-3C6B29D60C00Q30241952-300E6B9B-E1A2-410A-A2E3-9C5DC942F779Q33562214-3E663B8D-59AF-4746-A8C2-6C44AACBBA63Q33631921-34F8E331-532F-4BFA-B1B9-EAD519D00497Q33664745-0708B8A8-6399-45CF-8DAD-D7B046173B82Q33776236-63043785-1A16-4ABD-9C10-ACCC47B4F615Q33921392-3144AAF2-1564-413F-B447-45BEC7532D47Q34099153-5CB3959F-D9D0-4201-8BA9-65A92725E4F7Q34398065-1149BBF0-60E5-46C0-B3F6-01F865920B4CQ34567151-45EB9324-C138-416D-BAF6-32D9CDB6BC7BQ34576535-C9DC88EF-F99E-48FE-B30A-E91E15AA7837Q34618210-4238307C-EA84-418D-A1F3-C2964F3383A3Q34619115-39BF2E89-9A78-464E-B567-8420215AA748Q34628781-F79959E7-9A19-43C3-B8FA-1F7D1B239B73Q34664870-CD917C55-DFC7-46D8-89F7-700E4F50D40AQ34878637-A58FF223-364A-43E2-BE29-8AA1A9B8AF01Q34992980-98B4848E-7FED-4180-B345-898CDC4DC84BQ35049058-AA5FA676-7395-40D4-9695-9D9610BBECD7Q35189566-C76B65F1-86C5-4968-B0B7-06CB4F8BE4E6Q35329472-631782E7-25C3-4438-9C19-2CC99A877816Q36117595-8E691744-A1F8-4880-8149-E2BC07CB9406Q36261125-F3C87C14-5516-4D2A-B2AA-BAC47BF364B8Q36419283-1037D1DF-4BD3-463E-A483-9397657E6283Q36918509-D9A21D62-6B0A-40A7-AB9A-DC080DE5F4BEQ36952106-3839ABCC-C14E-40D1-825F-66E3D840471DQ37161933-202D5847-DFA4-473B-96DF-AF323EE6B8CCQ37288105-D84C4F29-8E9C-47FA-B8FA-57A8C405EF4CQ37298699-938A69FF-D20A-4F09-8E0F-57AC7A2E2329Q37556648-30123662-A49D-45AB-86B3-5854223DBB84Q37597024-1269775F-C488-4E7C-B02E-7157BF002136Q37622614-CA57D398-1FA2-4C43-A83C-0588DDC2A7A6
P2860
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@ast
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@en
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@nl
type
label
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@ast
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@en
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@nl
prefLabel
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@ast
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@en
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@nl
P2093
P921
P1433
P1476
Effect of the dual peroxisome ...... andomised, dose-ranging study.
@en
P2093
A Michael Lincoff
Cathy Chognot
Matthias Herz
Michael Rabbia
Robert R Henry
Sunder Mudaliar
P304
P356
10.1016/S0140-6736(09)60870-9
P407
P577
2009-06-08T00:00:00Z